Moderate

HIV - antiretroviral initiation & long-term management

ART start · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Lifelong combination antiretroviral therapy (ART) is offered to all people with HIV regardless of CD4 count, started rapidly (same-day where feasible) to suppress viraemia, restore immunity and prevent transmission (U=U). An integrase inhibitor-based regimen is first line for most.

Red flags

  • CD4 under 100 with headache or visual change (cryptococcal/toxoplasma)
  • New respiratory failure after ART start (PCP, IRIS)
  • Jaundice or rising transaminases
  • Features of disseminated TB
  • Severe rash with mucosal involvement or systemic features

Assessment

Differential diagnosis

  • Acute seroconversion illness
  • Advanced HIV with opportunistic infection
  • Immune reconstitution inflammatory syndrome
  • ART failure / resistance
  • Drug toxicity mimicking disease
  • Co-infection (TB, hepatitis B/C)

Investigations

  • Confirmatory HIV antigen/antibody plus viral load
  • CD4 count and percentage
  • HIV genotypic resistance test (baseline)
  • HLA-B*5701 before abacavir
  • Hepatitis B surface antigen, hepatitis C antibody, hepatitis A immunity
  • Renal and liver profile, lipids, HbA1c, pregnancy test
  • Screen for latent TB and STIs

Management

  • Confirm diagnosis and counsel; assess readiness and disclose U=U concept
  • Exclude or treat cryptococcal and TB disease before rapid start if CD4 very low or symptomatic
  • Send baseline bloods including genotype, HLA-B*5701, hepatitis serology, CD4, viral load
  • Choose a first-line integrase-inhibitor regimen; offer same-day or within-7-day start if ready
  • Avoid dolutegravir drug interactions (antacids, polyvalent cations, rifampicin dose adjustment)
  • Screen and vaccinate (hepatitis B, pneumococcal, influenza, COVID-19, HPV, mpox where indicated)
  • Start opportunistic-infection prophylaxis per CD4 threshold
  • Review adherence and tolerability at 2-4 weeks
  • Repeat viral load at 4-8 weeks then 3-6 monthly; target undetectable by 24 weeks
  • Monitor for immune reconstitution inflammatory syndrome in the first weeks
  • Arrange long-term monitoring of renal, bone, metabolic and cardiovascular risk
  • Link to specialist HIV service for continuity

Drugs & doses

Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg PO once daily
Dolutegravir 50 mg PO once daily plus emtricitabine/tenofovir (alternative backbone)
Dolutegravir/lamivudine 50/300 mg PO once daily (two-drug regimen if eligible)
Co-trimoxazole 960 mg PO once daily if CD4 under 200 (PCP prophylaxis)
Dolutegravir 50 mg PO twice daily if co-administered with rifampicin

Disposition

Outpatient specialist HIV clinic; admit if opportunistic infection or severe toxicity; urgent ID input for advanced disease.

Complications & pitfalls

  • Immune reconstitution inflammatory syndrome
  • Drug toxicity (renal, hepatic, hypersensitivity, weight gain)
  • Virological failure and resistance
  • Opportunistic infection before immune recovery
  • Drug-drug interactions causing subtherapeutic levels

Exam pearls

  • Undetectable equals untransmittable (U=U) once suppressed and sustained
  • Dolutegravir is preferred in pregnancy with no meaningful neural-tube signal on current data
  • Tenofovir-containing regimens also treat hepatitis B co-infection; do not stop abruptly
  • Rapid/same-day start improves linkage and viral suppression
  • Check for cryptococcal antigen if CD4 under 100 before starting

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.